Are we about to see a return for the pharma mega-merger?
There are rumours that the first pharma 'mega-merger' for several years – between AstraZeneca and Bristol Myers Squibb – is under discussion.
Newsletters and Deep Dive digital magazine
There are rumours that the first pharma 'mega-merger' for several years – between AstraZeneca and Bristol Myers Squibb – is under discussion.
AstraZeneca and Daiichi Sankyo's Datroway enters the first-line triple-negative breast cancer market in the EU, taking on Gilead's Trodelvy.
Replimune's RP1 immunotherapy for melanoma clears advisory committee vote by 10 to three, despite FDA concerns about the design of the IGNYTE study.
Hogan Lovells partner Alice Valder Curran returned to elucidate some of the finer points of the latest communication from CMS.
Cytokinetics gets simultaneous MHRA and NICE approvals for hypertrophic cardiomyopathy (HCM) therapy Myqorzo.
Editor's Picks
Newsletters and Deep Dive
digital magazine
Editor's Picks